actinium ac 225 gpc3-targeted peptide ryz801
Generic: Actinium Ac 225 GPC3-targeted Peptide RYZ801
actinium ac 225 gpc3-targeted peptide ryz801: 1 clinical trial tracked.
actinium ac 225 gpc3-targeted peptide ryz801 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about actinium ac 225 gpc3-targeted peptide ryz801, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)
Primary endpoint: Therapeutic - RYZ801
InterventionalRandomizedsingle590 targetStarted 2025-09Completion 2031-0613 sites · United StatesRayzeBio, Inc.